• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PCMT1 是一种潜在的预后生物标志物，与乳腺癌中的免疫浸润相关。

PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer.

机构信息

Department of Obstetrics and Gynecology, Jinniu District Maternal and Child Health Hospital, Chengdu, China.

出版信息

Biomed Res Int. 2022 Apr 30;2022:4434887. doi: 10.1155/2022/4434887. eCollection 2022.

DOI:10.1155/2022/4434887
PMID:35535040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9078795/
Abstract

BACKGROUND

Protein-L-isoaspartate (D-aspartate) O-methyltransferase () is involved in the occurrence and development of a variety of malignant tumors. However, the prognostic value of in breast cancer remains unclear.

METHODS

Based on the Cancer Genome Atlas database, we assessed the correlation between the expression of and prognosis, immune invasion, and tumor mutation burden in a variety of cancers. The expression level, mutation, immune correlation, and coexpression of in breast cancer were studied using the following databases: UALCAN database, Human Protein Atlas database, cBioPortal database, TIMER database, and LinkedOmics database. Kaplan-Meier Plotter was used for survival analysis. Receiver operating characteristic (ROC) curves and nomograms were drawn using the R software package. < 0.05 was considered statistically significant.

RESULTS

Pancancer analysis showed that is highly expressed in a variety of cancers and is significantly related to the prognosis of a variety of cancers. is significantly related to the tumor mutation burden of a variety of cancers. is significantly high in breast cancer, and it is significantly related to the abundance of immune infiltration. Survival analysis revealed that high expression is significantly associated with shorter overall survival (OS), relapse-free survival (RFS), and postprogression survival (PPS) in breast cancer patients. ROC curves and nomograms verify the effectiveness of as a prognostic biomarker for breast cancer.

CONCLUSIONS

PCMT1 can be used as a potential prognostic biomarker of breast cancer, and it is significantly related to the abundance of breast cancer immune infiltration.

摘要

背景

蛋白质-L-异天冬氨酸（D-天冬氨酸）O-甲基转移酶（）参与多种恶性肿瘤的发生和发展。然而，在乳腺癌中，的预后价值尚不清楚。

方法

基于癌症基因组图谱数据库，我们评估了在多种癌症中与预后、免疫浸润和肿瘤突变负担相关的表达。使用以下数据库研究乳腺癌中表达水平、突变、免疫相关性和共表达：UALCAN 数据库、人类蛋白质图谱数据库、cBioPortal 数据库、TIMER 数据库和 LinkedOmics 数据库。 Kaplan-Meier Plotter 用于生存分析。使用 R 软件包绘制Receiver operating characteristic（ROC）曲线和列线图。<0.05 被认为具有统计学意义。

结果

泛癌症分析表明，在多种癌症中高表达，与多种癌症的预后显著相关。与多种癌症的肿瘤突变负担显著相关。在乳腺癌中显著高表达，与免疫浸润丰度显著相关。生存分析表明，高表达与乳腺癌患者的总生存期（OS）、无复发生存期（RFS）和进展后生存期（PPS）较短显著相关。ROC 曲线和列线图验证了作为乳腺癌预后生物标志物的有效性。

结论

PCMT1 可作为乳腺癌潜在的预后生物标志物，与乳腺癌免疫浸润丰度显著相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/f6e1226ab20d/BMRI2022-4434887.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/b7c6eb5ec81b/BMRI2022-4434887.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/473d866e92f5/BMRI2022-4434887.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/e3295b3442eb/BMRI2022-4434887.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/c1194e95a02f/BMRI2022-4434887.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/8b9d8411bd30/BMRI2022-4434887.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/bbffa9ac70c5/BMRI2022-4434887.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/22e1d6adf0af/BMRI2022-4434887.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/f6e1226ab20d/BMRI2022-4434887.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/b7c6eb5ec81b/BMRI2022-4434887.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/473d866e92f5/BMRI2022-4434887.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/e3295b3442eb/BMRI2022-4434887.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/c1194e95a02f/BMRI2022-4434887.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/8b9d8411bd30/BMRI2022-4434887.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/bbffa9ac70c5/BMRI2022-4434887.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/22e1d6adf0af/BMRI2022-4434887.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7c/9078795/f6e1226ab20d/BMRI2022-4434887.008.jpg

相似文献

1
PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer.PCMT1 是一种潜在的预后生物标志物，与乳腺癌中的免疫浸润相关。
Biomed Res Int. 2022 Apr 30;2022:4434887. doi: 10.1155/2022/4434887. eCollection 2022.
2
[Prognostic Value of PCMT1 Expression in Gastric Cancer and Its Regulatory Effect on Spindle Assembly Checkpoints].[PCMT1表达在胃癌中的预后价值及其对纺锤体组装检查点的调节作用]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Nov 20;54(6):1167-1175. doi: 10.12182/20231160211.
3
PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer.PCMT1 是膀胱癌的一个不利预后预测因子和癌基因。
IUBMB Life. 2018 Apr;70(4):291-299. doi: 10.1002/iub.1717. Epub 2018 Mar 8.
4
In vitro Anti-malignant Property of PCMT1 Silencing and Identification of the SNHG16/miR-195/PCMT1 Regulatory Axis in Breast Cancer Cells.PCMT1 沉默的体外抗恶性特性及 SNHG16/miR-195/PCMT1 调控轴在乳腺癌细胞中的鉴定。
Clin Breast Cancer. 2023 Apr;23(3):302-316. doi: 10.1016/j.clbc.2022.12.013. Epub 2022 Dec 24.
5
PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.PCMT1 是肝癌中与肿瘤进展和免疫浸润相关的潜在靶点。
Eur J Med Res. 2023 Aug 18;28(1):289. doi: 10.1186/s40001-023-01216-1.
6
Elevated expression of protein-L-isoaspartate O-methyltransferase-1 (PCMT1) in cervical cancer.蛋白质-L-异天冬氨酸O-甲基转移酶-1（PCMT1）在宫颈癌中的表达升高。
Transl Cancer Res. 2022 Aug;11(8):2582-2590. doi: 10.21037/tcr-21-2700.
7
SEMA7A as a Novel Prognostic Biomarker and Its Correlation with Immune Infiltrates in Breast Cancer.SEMA7A作为一种新型的预后生物标志物及其与乳腺癌免疫浸润的相关性。
Int J Gen Med. 2024 Sep 14;17:4081-4099. doi: 10.2147/IJGM.S474827. eCollection 2024.
8
Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer.全面分析 G2E3 在乳腺癌中的表达、预后意义和调控途径。
World J Surg Oncol. 2022 Dec 15;20(1):398. doi: 10.1186/s12957-022-02871-0.
9
PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells.PCMT1 敲低通过全局调控三阴性乳腺癌细胞的转录组谱来抑制恶性特征。
PeerJ. 2023 Nov 6;11:e16006. doi: 10.7717/peerj.16006. eCollection 2023.
10
Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.通过生物信息学分析鉴定 LCN1 作为乳腺癌的潜在生物标志物。
DNA Cell Biol. 2019 Oct;38(10):1088-1099. doi: 10.1089/dna.2019.4843. Epub 2019 Aug 19.

引用本文的文献

1
Telomere Maintenance-Related Genes are Essential for Prognosis in Breast Cancer.端粒维持相关基因对乳腺癌预后至关重要。
Breast Cancer (Dove Med Press). 2025 Feb 24;17:225-239. doi: 10.2147/BCTT.S506783. eCollection 2025.
2
PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis.PCMT1被确认为一种泛癌免疫生物标志物以及乳腺癌转移的一个促成因素。
Am J Cancer Res. 2024 Aug 25;14(8):3711-3732. doi: 10.62347/TYLL7952. eCollection 2024.
3
PCMT1 as a prognostic marker in breast cancer.PCMT1作为乳腺癌的一种预后标志物。

本文引用的文献

1
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.对整个转录组进行生存分析可识别出乳腺癌中具有最高预后能力的生物标志物。
Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109. doi: 10.1016/j.csbj.2021.07.014. eCollection 2021.
2
bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses.bc-GenExMiner 4.5：新的挖掘模块计算乳腺癌差异基因表达分析。
Database (Oxford). 2021 Feb 18;2021. doi: 10.1093/database/baab007.
3
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Clin Transl Oncol. 2025 Apr;27(4):1558-1568. doi: 10.1007/s12094-024-03695-y. Epub 2024 Sep 5.
4
Insights into a Machine Learning-Based Palmitoylation-Related Gene Model for Predicting the Prognosis and Treatment Response of Breast Cancer Patients.基于机器学习的棕榈酰化相关基因模型预测乳腺癌患者预后和治疗反应的研究进展。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241263434. doi: 10.1177/15330338241263434.
5
Triterpenoid ursolic acid regulates the environmental carcinogen benzo[a]pyrene-driven epigenetic and metabolic alterations in SKH-1 hairless mice for skin cancer interception.三萜熊果酸调控环境致癌物苯并[a]芘诱导的 SKH-1 无毛小鼠皮肤癌变的表观遗传和代谢改变。
Carcinogenesis. 2024 May 19;45(5):288-299. doi: 10.1093/carcin/bgae009.
6
[Prognostic Value of PCMT1 Expression in Gastric Cancer and Its Regulatory Effect on Spindle Assembly Checkpoints].[PCMT1表达在胃癌中的预后价值及其对纺锤体组装检查点的调节作用]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Nov 20;54(6):1167-1175. doi: 10.12182/20231160211.
7
Breaking tolerance: autoantibodies can target protein posttranslational modifications.打破耐受：自身抗体可以靶向蛋白质翻译后修饰。
Curr Opin Biotechnol. 2024 Feb;85:103056. doi: 10.1016/j.copbio.2023.103056. Epub 2023 Dec 22.
8
PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells.PCMT1 敲低通过全局调控三阴性乳腺癌细胞的转录组谱来抑制恶性特征。
PeerJ. 2023 Nov 6;11:e16006. doi: 10.7717/peerj.16006. eCollection 2023.
9
Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity.系统性幼年特发性关节炎（SJIA）患者的自身抗体特征因疾病活动度而异。
Biomolecules. 2023 Sep 15;13(9):1392. doi: 10.3390/biom13091392.
10
PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.PCMT1 是肝癌中与肿瘤进展和免疫浸润相关的潜在靶点。
Eur J Med Res. 2023 Aug 18;28(1):289. doi: 10.1186/s40001-023-01216-1.
乳腺癌中基于大分子和细胞的生物标志物的最新发现及治疗意义。
Int J Mol Sci. 2021 Jan 10;22(2):636. doi: 10.3390/ijms22020636.
4
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
5
New biomarkers in SLE: from bench to bedside.SLE 中的新型生物标志物：从实验室到临床。
Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v12-v18. doi: 10.1093/rheumatology/keaa484.
6
Use of high-resolution full-field optical coherence tomography and dynamic cell imaging for rapid intraoperative diagnosis during breast cancer surgery.使用高分辨率全场光学相干断层扫描和动态细胞成像技术在乳腺癌手术中进行快速术中诊断。
Cancer. 2020 Aug 15;126 Suppl 16:3847-3856. doi: 10.1002/cncr.32838.
7
Protein Kinase C Theta Modulates PCMT1 through hnRNPL to Regulate FOXP3 Stability in Regulatory T Cells.蛋白激酶 Cθ 通过 hnRNPL 调节 PCMT1 以调节调节性 T 细胞中 FOXP3 的稳定性。
Mol Ther. 2020 Oct 7;28(10):2220-2236. doi: 10.1016/j.ymthe.2020.06.012. Epub 2020 Jun 15.
8
Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups.用于评估胶质瘤组肿瘤免疫微环境及预测预后的缺氧特征分析
Front Oncol. 2020 May 15;10:796. doi: 10.3389/fonc.2020.00796. eCollection 2020.
9
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
10
Pan-cancer analysis of whole genomes.泛癌症全基因组分析。
Nature. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5.